Aquilante CL - Search Results

1

Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography.

Aquilante CL, Humma LM, Yarandi HN, Andrisin TE, Lewis JF, Hamilton KK, Johnson JA. Aquilante CL, et al. Am J Cardiol. 2004 Aug 15;94(4):535-8. doi: 10.1016/j.amjcard.2004.04.076. Am J Cardiol. 2004. PMID: 15325950

2

Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography.

Aquilante CL, Yarandi HN, Cavallari LH, Andrisin TE, Terra SG, Lewis JF, Hamilton KK, Johnson JA. Aquilante CL, et al. Pharmacogenomics J. 2008 Dec;8(6):408-15. doi: 10.1038/sj.tpj.6500490. Epub 2008 Feb 5. Pharmacogenomics J. 2008. PMID: 18253135

3

Sequencing drug response with HapMap.

Lin M, Aquilante C, Johnson JA, Wu R. Lin M, et al. Pharmacogenomics J. 2005;5(3):149-56. doi: 10.1038/sj.tpj.6500302. Pharmacogenomics J. 2005. PMID: 15782224

4

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Aquilante CL, et al. Clin Pharmacol Ther. 2006 Apr;79(4):291-302. doi: 10.1016/j.clpt.2005.11.011. Epub 2006 Feb 28. Clin Pharmacol Ther. 2006. PMID: 16580898 Clinical Trial.

5

Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure.

Aquilante CL, Terra SG, Schofield RS, Pauly DF, Hatton PS, Binkley PF, Johnson JA. Aquilante CL, et al. J Card Fail. 2006 Apr;12(3):171-6. doi: 10.1016/j.cardfail.2005.12.002. J Card Fail. 2006. PMID: 16624680 Clinical Trial.

6

Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory.

Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Aquilante CL, et al. Pharmacotherapy. 2004 Jun;24(6):720-6. doi: 10.1592/phco.24.8.720.36074. Pharmacotherapy. 2004. PMID: 15222661

7

Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.

Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, Duong BQ, Petry NJ, Aquilante CL, Beitelshees AL, Empey PE, Johnson JA, Obeng AO, Pasternak AL, Pratt VM, Ramsey LB, Tuteja S, Van Driest SL, Wiisanen K, Hicks JK, Cavallari LH; IGNITE Network Pharmacogenetics Working Group. Duarte JD, et al. Among authors: aquilante cl. Genet Med. 2021 Dec;23(12):2335-2341. doi: 10.1038/s41436-021-01269-9. Epub 2021 Jul 19. Genet Med. 2021. PMID: 34282303 Free PMC article.

8

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Gage BF, et al. Among authors: aquilante cl. Clin Pharmacol Ther. 2008 Sep;84(3):326-31. doi: 10.1038/clpt.2008.10. Epub 2008 Feb 27. Clin Pharmacol Ther. 2008. PMID: 18305455 Free PMC article.

9

Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.

Aquilante CL, Zhang W, McCollum M. Aquilante CL, et al. Curr Med Res Opin. 2007 Mar;23(3):489-94. doi: 10.1185/030079906X167354. Curr Med Res Opin. 2007. PMID: 17355730

10

Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms.

Pacanowski MA, Hopley CW, Aquilante CL. Pacanowski MA, et al. Among authors: aquilante cl. Expert Opin Drug Metab Toxicol. 2008 May;4(5):529-44. doi: 10.1517/17425255.4.5.529. Expert Opin Drug Metab Toxicol. 2008. PMID: 18484913 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

88 results

Search Page